Blastulation rates decline in a linear fashion from euploid to aneuploid embryos with single versus multiple chromosomal errors
Euploid embryos are far more likely than aneuploid embryos to progress to the blastocyst stage with a linear decrease in probability of blastulation with increasing number of chromosomal abnormalities.
Mario Vega, M.D., Andrzej Breborowicz, M.D., Ph.D., Erin Moshier, M.S., Peter McGovern, M.D., Martin Keltz, M.D.,
Volume 102, Issue 2, Pages 394–398
To test the hypothesis that the blastulation rate is higher in euploid embryos than in aneuploid embryos as assessed by cleavage-stage biopsy with array-comprehensive genomic hybridization (aCGH).
Retrospective cohort study.
Forty-one patients with 48 in vitro fertilization (IVF) cycles and 385 embryos that underwent cleavage-stage preimplantation genetic screening (PGS) with aCGH at the Continuum Reproductive Center between January 2010 and September 2013.
Main Outcome Measure(s):
Probability of blastocyst and/or fully expanded or hatching blastocyst (FEHB) progression depending on number of chromosomal abnormalities.
Euploid embryos are twice as likely to progress to blastocyst and three times as likely to progress to FEHB than aneuploid embryos: 76% versus 37% and 56% versus 18%, respectively. For every additional chromosomal abnormality, the likelihood of progressing to the blastocyst stage decreases by 22% and the likelihood of progressing to FEHB decreases by 33%.
Euploid embryos are far more likely than aneuploid embryos to progress to the blastocyst and FEHB stages. There is a linear decrease in probability of blastulation with the increasing number of chromosomal abnormalities.